Welcome to our dedicated page for Integra LifeSciences Holdings news (Ticker: IART), a resource for investors and traders seeking the latest updates and insights on Integra LifeSciences Holdings stock.
Integra LifeSciences Holdings Corporation reports developments as a global medical technology company focused on neurosurgery and tissue reconstruction. News commonly covers quarterly financial results, revenue guidance, operational execution, supply reliability, quality-management work and product availability across its medical technology portfolio.
Company updates also include clinical evidence and medical-conference activity for wound reconstruction products such as PriMatrix Dermal Scaffold, Integra Dermal Matrices, Cytal Wound Matrix, MicroMatrix and AmnioExcel. Recurring corporate topics include leadership appointments, investor conference presentations, manufacturing progress and segment activity within Codman Specialty Surgical and Tissue Technologies.
Integra LifeSciences (IART) will present at the 2026 Wells Fargo Healthcare Conference on September 9, 2026, at 2:15 p.m. ET, and at the 2026 Morgan Stanley Healthcare Conference on September 15, 2026, at 4:05 p.m. ET.
Presenters include the chief financial officer, chief commercial officer, and the chairman and chief executive officer. A live webcast of both presentations will be accessible through the company’s investor relations website under Events & Presentations.
Integra LifeSciences (Nasdaq:IART) reported second quarter 2026 revenue of $418.8 million, up 0.8% reported and 0.7% organic year over year. GAAP EPS was $0.06, versus a loss of $(6.31) a year ago, while adjusted EPS rose to $0.56 from $0.45.
GAAP gross margin improved to 52.5% and adjusted gross margin to 61.3%. Adjusted EBITDA reached $78.4 million (18.7% margin). Specialty Surgery revenue grew 1.7% to $309.3 million, while Tissue Reconstruction declined 1.9% to $109.5 million. Operating cash flow was $22.8 million, net debt was $1.6 billion, and liquidity totaled about $496 million.
For Q3 2026, Integra expects revenue of $410–$425 million and adjusted EPS of $0.53–$0.61. Full‑year reported revenue guidance was slightly reduced to $1.654–$1.695 billion for FX, while organic growth guidance of 0.8%–3.3% and adjusted EPS of $2.40–$2.50 were reaffirmed. The company also initiated production at its Braintree facility ahead of the planned Q4 SurgiMend relaunch.
Integra LifeSciences (NASDAQ: IART) will release its second quarter 2026 financial results on Wednesday, July 29, 2026, before the market opens. Management will host an earnings conference call at 8:30 a.m. ET, with a live webcast and replay available in the Investors section of the company’s website.
Integra LifeSciences (Nasdaq:IART) appointed Topaz Kirlew as corporate vice president and chief regulatory officer, leading global regulatory affairs and strategy.
She previously served as interim regulatory leader, overseeing compliance, submissions, and risk mitigation, and brings over 35 years of healthcare and medical technology experience across regulatory, quality, operations, clinical, and laboratory roles.
Integra LifeSciences (Nasdaq:IART) announced key leadership appointments in its commercial organization to support long-term growth and customer focus.
Robert T. Davis Jr. becomes EVP, Tissue Reconstruction and Distributed Technologies; Christopher Kilburn-Peterson is promoted to corporate VP and president, Tissue Reconstruction; Harvinder Singh becomes EVP and president, Specialty Surgery, while international leaders now report to chief commercial officer Mike McBreen.
Integra LifeSciences (Nasdaq:IART) announced that Bob Davis, executive vice president and president Tissue Reconstruction, will present at the 2026 Truist Securities MedTech Conference on June 16, 2026, at 3:00pm ET.
A live webcast of the presentation will be available on the company’s investor relations website under Events & Presentations.
Integra LifeSciences (Nasdaq:IART) announced that chief financial officer Lea Knight will present at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 10:30am ET.
A live webcast of the presentation will be available on the company’s investor relations website under Events & Presentations.
Integra LifeSciences (Nasdaq: IART) announced that CFO Lea Knight will present at the BofA Securities 2026 Health Care Conference on May 12, 2026 at 4:20pm PT. A live webcast will be available on the Integra investor relations site under Events & Presentations.
Integra LifeSciences (NASDAQ: IART) announced a leadership transition effective May 1, 2026: Stuart M. Essig has been appointed president and chief executive officer and will continue as chairman, succeeding Mojdeh Poul, who is pursuing other opportunities. Michael McBreen is named chief commercial officer to lead the global commercial organization.
The Board said this is a permanent leadership step and will not initiate a CEO search. Mr. Essig previously served as Integra CEO (1997–2012) and has chaired the Board since 2012.
Integra LifeSciences (Nasdaq: IART) reported Q1 2026 results: revenue $391.9M (+2.4% reported, +1.3% organic), GAAP EPS $(0.06), and adjusted EPS $0.54. Adjusted EBITDA was $76.2M (19.4% of revenue). Company reaffirmed 2026 revenue guidance of $1.662B–$1.702B and raised adjusted EPS guidance to $2.40–$2.50.
Net debt was $1.6B, liquidity ~$488M, and management transitions included Stuart Essig as CEO and Michael McBreen as Chief Commercial Officer.